Assessment of cytotoxicity, genotoxicity, and mutagenicity of the dexchlorpheniramine reference standard and pharmaceutical formula in human peripheral blood mononuclear cells

Authors

  • Pamella Eduardha Espindola Chaves TOXCEL - Grupo de Pesquisa em Toxicologia Celular, Universidade Federal do Pampa, Uruguaiana, Brasil
  • Luísa Zuravski TOXCEL - Grupo de Pesquisa em Toxicologia Celular, Universidade Federal do Pampa, Uruguaiana, Brasil
  • Anelise Santos Soares TOXCEL - Grupo de Pesquisa em Toxicologia Celular, Universidade Federal do Pampa, Uruguaiana, Brasil
  • Lavínia Veiga Pereira TOXCEL - Grupo de Pesquisa em Toxicologia Celular, Universidade Federal do Pampa, Uruguaiana, Brasil
  • Élvio Adílio Serpa TOXCEL - Grupo de Pesquisa em Toxicologia Celular, Universidade Federal do Pampa, Uruguaiana, Brasil; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Pampa, Uruguaiana, Brasil
  • Luís Flávio Souza Oliveira TOXCEL - Grupo de Pesquisa em Toxicologia Celular, Universidade Federal do Pampa, Uruguaiana, Brasil; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Pampa, Uruguaiana, Brasil
  • Michel Mansur Machado TOXCEL - Grupo de Pesquisa em Toxicologia Celular, Universidade Federal do Pampa, Uruguaiana, Brasil; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Pampa, Uruguaiana, Brasil; GIGA – Grupo de Imunologia e Genética Aplicada, Universidade Federal do Pampa, Uruguaiana, Brasil https://orcid.org/0000-0002-7583-9332

DOI:

https://doi.org/10.1590/s2175-97902022e20096%20%20

Keywords:

Dexchlorpheniramine, PBMC, In vitro, DNA

Abstract

Dexchlorpheniramine is a first-generation classical antihistamine, clinically used to treat allergies. The main objective of our study was to evaluate the effects of the dexchlorpheniramine reference standard (DCPA Ref. St) and a pharmaceutical formula on DNA in human peripheral blood mononuclear cells (PBMCs). We exposed PBMCs to five different concentrations (0.5, 2.5, 5, 10, and 50 ng/mL) of DCPA Ref. St DCPA Ref. St and pharmaceutical formula in order to evaluate their cytotoxic, genotoxic, and mutagenic potential. The results showed that both dexchlorpheniramine formulations did not affect PBMC viability and CD3+, CD4+, or CD8+ lymphocyte subpopulations. The DCPA Ref. St and pharmaceutical formula neither induced genotoxic or mutagenic effects nor numerical or structural chromosomal alterations in PBMCs after 24 hours of exposure.

Downloads

Download data is not yet available.

References

Boner A, Miglioranzi P, Richelli C, Marchesi E, Andreoli A. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis. Allergy. 1989;44(6):437-441.

Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, et al. Differences in susceptibility to tumor necrosis factor α-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res. 1998;58(21):4940-4946.

Calle OC, Fernandez-Benitez M. Allergy to dexchlorpheniramine. Study of a case. Allergol Immunopath. 2004;32(5):306-309.

Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013;58(3):219.

de Moura Leão MF, Duarte JA, Sauzen PD, Piccoli JdCE, de Oliveira LFS, Machado MM. Cytotoxic and genotoxic effects of antihypertensives distributed in Brazil by social programs: Are they safe? Environ Toxicol Pharmacol. 2018;63:1-5.

Desai R, Sehgal N. Patient with Renal Failure. In: (Ed.). Guide to the Inpatient Pain Consult: Springer, 2020; p.123-129.

Gobo-Oliveira M, Pigari VG, Ogata MS, Miot HA, Ponce D, Abbade LP. Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. Eur J Dermatol. 2018;28(4):488-495.

Jacob RS, Santos LVdS, de Souza AFR, Lange LC. A toxicity assessment of 30 pharmaceuticals using Aliivibrio fischeri: a comparison of the acute effects of different formulations. Environ Technol. 2016;37(21):2760-2767.

Johansen L, Bjerrum P, Illum P. Treatment of seasonal allergic rhinitis--a double blind, group comparative study of terfenadine and dexchlorpheniramine. Rhinology. 1987;25(1):35-40.

Kontaş S, Atlı Şekeroğlu Z. Investigation of cytotoxic and genotoxic effects of the antihistaminic drug, loratadine, on human lymphocytes. Drug Chem Toxicol. 2015;38(1):57-62.

Kordulewska NK, Kostyra E, Matysiewicz M, Cieślińska A, Jarmołowska B. Impact of fexofenadine, osthole and histamine on peripheral blood mononuclear cell proliferation and cytokine secretion. Eur J Pharmacol. 2015;761:254-261.

Moreno RA, Oliveira-Silva D, Sverdloff CE, Borges BC, Rebelo Galvinas PA, Astigarraga RB, et al. Determination of chlorpheniramine in human plasma by HPLC-ESI-MS/ MS: application to a dexchlorpheniramine comparative bioavailability study. Biomed Chromatogr. 2010;24(7):774- 781.

LI P, Liu L, Ma P, Wang L, Chi X, Liang D, et al. Pharmacokinetics of Paracetamol and Dexchlorpheniramine maleate oral solution in healthy volunteers. J Beijing Norm Univ (Nat Sci). 2008;03.

Ricciardi L, Furci F, Stefania I. H1-Antihistamines for allergic diseases: old aged but not old-fashioned drugs. Int J Aller Medications. 2019;5(1):037.

Rich RR, Chaplin DD. The human immune response. In: (Ed.). Clinical Immunology: Elsevier. 2019; p.3-17. e1.

Sanchez-Borges M, Ansotegui IJ. Second generation antihistamines: an update. Curr Opin in Allergy Clin Immunol. 2019;19(4):358-364.

Schmid W. The micronucleus test. Mutat Res, Environ Mutagen Relat Subj. 1975;31(1):9-15.

Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175(1):184-191.

Yunis JJ. High resolution of human chromosomes. Science. 1976;191(4233):1268-1270.

Downloads

Published

2022-12-23

Issue

Section

Original Article

How to Cite

Assessment of cytotoxicity, genotoxicity, and mutagenicity of the dexchlorpheniramine reference standard and pharmaceutical formula in human peripheral blood mononuclear cells. (2022). Brazilian Journal of Pharmaceutical Sciences, 58. https://doi.org/10.1590/s2175-97902022e20096